Skip to main content

Neuroscience

Neuroscience Research Institute

Clinical Trials

Showing 1-9 out of 15 results.
NCT05364021

A Phase 1b/2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Dose-Escalation Study to Investigate the Safety, Tolerability, pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies

Icon for trial | LP352-201 A Phase 1b/2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Dose-Escalation Study to Investigate the Safety, Tolerability, pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of LP352 in Subjects With Developmental and E

This study is currently enrolling.

LP352 is being studied to see if it might reduce the number of seizures in patients with DEE. LP352 is thought to work by activating specific sites in the brain that are associated with seizure disorders.

NCT05237284

A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an open-label extension

Icon for trial | ACT16970 A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an open-label extension

This study is currently enrolling.

The purpose of the study is to evaluate twice daily (BID) oral doses of the investigational drug SAR443820 compared to placebo (which has no active medication) in addition to the standard of care, (e.g. riluzole or edaravone) f ...